Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice

Arch Pharmacol Ther. 2020;2(1):6-8.

Authors

Muhammad Wasif Saif^{1

2}, Hilal Hachem², Sneha Purvey², Ruchi Hamal², Lulu Zhang², Nauman Saleem Siddiqui², Amandeep Godara², Robert B Diasio³

Affiliations

¹ Northwell Health Cancer Institute, Lake Success, NY 11042, USA.
² Tufts Medical Center, Boston, MA, 02110, USA.
³ Mayo Clinic, Rochester, MN, Rochester, MN, USA.

PMID: 33283204
PMCID: PMC7713499

No abstract available

Keywords: 5-Fluorouracil; Capecitabine; DPYD gene; Fluoropyrimidines.

Grants and funding

R01 CA085381/CA/NCI NIH HHS/United States